ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalidomide Maintenance After ASCT
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalidomid…
2022年12月18日
vumedi.com
Therapy for Newly Diagnosed Myeloma - Role of Transplant and MRD, DARA-VRd vs.VRd Trial, Lenalidomide Maintenance Therapy, Achieving MRD- with ASCT and Adding Isatuximab to VRd
Therapy for Newly Diagnosed Myeloma - Role of Transplant and M…
2019年6月8日
vumedi.com
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) | OncLive
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Thera…
2025年1月30日
onclive.com
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study | OncLive
11:34
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Ne…
10 个月之前
onclive.com
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study | OncLive
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lena…
2022年12月22日
onclive.com
Daratumumab Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study | OncLive
5:53
Daratumumab Bortezomib/Lenalidomide/Dexameth…
2024年10月14日
onclive.com
Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma | OncLive
Dr Anderson on Daratumumab/Lenalidomide Mainten…
8 个月之前
onclive.com
Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 St…
2025年4月1日
onclive.com
ATLAS Trial Confirms Superior Myeloma Survival With KRd Mainten…
1 周前
targetedonc.com
La FDA approuve le daratumumab et l'hyaluronidase-fihj associés au borté…
3 个月之前
zonebourse.com
3:58
Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL | OncLive
2025年2月4日
onclive.com
11:07
EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rit…
2024年1月23日
onclive.com
3:01
Next-Generation Therapies Target High-Risk Smoldering Multiple Myelo…
5 个月之前
ajmc.com
VIDEO: Four drugs 'appear to be better' in treatment of newly diagnos…
10 个月之前
healio.com
Contro mieloma multiplo Lenalidomide rimborsato in Italia nel post-trapianto
2018年6月26日
dire.it
Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-L…
2023年12月21日
onclive.com
Tafasitamab Lenalidomide vs. CIT for Transplant-Ineligible R/R DLBCL
已浏览 354 次2024年9月30日
vumedi.com
Tafasitamab Lenalidomide Therapy in Relapsed/Refractory DLBCL | OncLive
2023年6月26日
onclive.com
Lenalidomide: Uses, Dosage, Side effects, Precautions, Interactions - Dr…
2025年1月24日
medindia.net
1:19
Dr Mateos on Ongoing Research With Cilta-Cel in Newly Diagnosed Multipl…
2025年4月9日
onclive.com
Revlimid (lenalidomide) effetti collaterali, interazioni, usi e impronta …
2019年8月21日
oldmedic.com
Development of a Low-dose Percutaneous Delivery System Lenal…
9 个月之前
labroots.com
Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalid…
11 个月之前
onclive.com
FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R …
11 个月之前
onclive.com
Novartis' Sandoz Launches Generic Lenalidomide in Europe
2022年2月18日
marketscreener.com
Daratumumab-based quadruplet therapy for transplant-eligible newly …
2024年4月24日
nih.gov
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myel…
2024年10月2日
onclive.com
Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Pati…
2015年1月20日
onclive.com
Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagno…
10 个月之前
finanznachrichten.de
观看更多视频
静态缩略图占位符